SCHEMBL22200535

SCHEMBL22200535

CSc1ncc2cc(-c3ccc(NSCc4ccccc4)c(F)c3F)c(OC(C)C(F)F)nc2n1

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 15/20 0.35
AKT2 P31751 15/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356303 0.85 BRAF (0.36) AKT1AKT2
SCHEMBL22191516 0.85 BRAF (0.36) AKT1AKT2
SCHEMBL22191217 0.78 AKT1 (0.33) AKT1AKT2
SCHEMBL29358839 0.78 AKT1 (0.33) AKT1AKT2
SCHEMBL22200682 0.73 FGFR1 (0.44)
SCHEMBL25035601 0.73 F2 (0.37)
SCHEMBL22200335 0.72 WEE1 (0.34)
SCHEMBL29352947 0.72 BRAF (0.36)
SCHEMBL22191327 0.72 BRAF (0.36)
SCHEMBL22191477 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed